What one share of Enveric Biosciences holds
We are a biotechnology company focused on developing next-generation, small-molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders. By leveraging a differentiated drug discovery platform and a growing library of patent protected chemical structures, we are advancing a pipeline of novel compounds designed to promote neuroplasticity without hallucinogenic effects.
Enveric Biosciences’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$5.44 |
|---|---|
| Cash and investments | $2.11 |
| Book value | $2.05 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2024 | — | −$228.48 | — | — | — | $28.19 |
| 2025 | — | −$36.24 | — | — | — | $3.94 |
Common questions about Enveric Biosciences
How much does one share of Enveric Biosciences earn?
Over the last 12 months, Enveric Biosciences lost $5.44 for each share.
Does Enveric Biosciences pay a dividend?
Enveric Biosciences didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Enveric Biosciences’s book value per share?
Enveric Biosciences’s book value is $2.05 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Enveric Biosciences have?
Each share of Enveric Biosciences has $2.11 of cash and investments, as of June 30, 2026.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.